Moyamoya disease in Southeast Asians: genetic and autopsy data, new cases, systematic review, and meta-analysis of all patients from the literature
- PMID: 38478032
- PMCID: PMC11136762
- DOI: 10.1007/s00415-024-12228-0
Moyamoya disease in Southeast Asians: genetic and autopsy data, new cases, systematic review, and meta-analysis of all patients from the literature
Abstract
Background: Moyamoya disease (MMD) is a rare disorder causing ischemic and hemorrhagic juvenile stroke. It is associated with the founder susceptibility variant p.R4810K in the RNF213 gene in East Asia. Our aim was to enhance understanding of MMD in so far poorly characterized Southeast Asians and exploring differences with Caucasian Europeans.
Methods: By retrospective analysis of medical records and systematic database search on PubMed for all published cases, we identified Southeast Asian patients with MMD. We extracted and pooled proportions using fixed-effects models. Our own cohort was tested for the East Asian RNF213 founder variant p.R4810K. One of our Southeast Asian patients underwent post-mortem histopathological examination.
Results: The study cohort comprised 32 Southeast Asians. Mean age at onset in the entire cohort was 32.5 ± 20.3 years (n = 24), 43.4 ± 8.7 years in patients admitted to our center (n = 11), and 23.4 ± 22.4 years in patients from the international literature (n = 13). Female-to-male ratio was 1.6:1. MMD predominantly affected bilateral anterior intracranial vessels. Cerebral ischemia outnumbered transient ischemic attacks (TIAs) and intracranial hemorrhage. TIAs, arterial hypertension and obesity were significantly less frequent in Southeast Asian patients compared to Caucasian Europeans. p.R4810K was absent in all examined Southeast Asians despite of typical histopathological signs of MMD in one autopsy case.
Conclusion: Clinical and histopathological manifestations of MMD in Southeast Asians are similar to those in Caucasian Europeans. The genotype of MMD in Southeast Asians differs from that of most East Asian patients.
Keywords: RNF213 p.R4810K variant; East Asian; European Caucasian; Histopathology; Moyamoya disease; Southeast Asian.
© 2024. The Author(s).
Conflict of interest statement
Daniel Strunk: There is no conflict of interest. Peter Bauer: is chief medical and genomic officer at Centigene AG Rostock. Kathy Keyvani: There is no conflict of interest. Rolf R. Diehl: There is no conflict of interest. Roland Veltkamp: RV is an investigator of the NIHR Imperial Biomedical Research Centre and reports fees for consulting and speaker honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Pfizer, Daichi Sankyo, Portola, Biogen, Medtronic, and Morphosys; and research grants from Bayer, Boehringer, Bristol Myers Squibb. Peter Berlit: There is no conflict of interest. Sven G. Meuth: There is no conflict of interest. Lars Timmermann: LT reports grants, personal fees, and non-financial support from SAPIENS Steering Brain Stimulation, Medtronic, Boston Scientific, and St. Jude Medical, and has received payments from Bayer Healthcare, UCB Schwarz Pharma, and Archimedes Pharma and also honoraria as a speaker on symposia sponsored by Teva Pharma, Lundbeck Pharma, Bracco, Gianni PR, Medas Pharma, UCB Schwarz Pharma, Desitin Pharma, Boehringer Ingelheim, GSK, Eumecom, Orion Pharma, Medtronic, Boston Scientific, Cephalon, Abbott, GE Medical, Archimedes, and Bayer. Jan Claudius Schwitalla: JCS is a full-time employee of Astra Zenica, but this article was written as part of his voluntary work on the board of the German Moyamoya Association. Markus Kraemer: MK received honoraria for lecture activities from Roche Pharma and Chugai without any connection to the topic of the article.
Figures


Similar articles
-
Disease Variant Landscape of a Large Multiethnic Population of Moyamoya Patients by Exome Sequencing.G3 (Bethesda). 2015 Nov 3;6(1):41-9. doi: 10.1534/g3.115.020321. G3 (Bethesda). 2015. PMID: 26530418 Free PMC article.
-
Distribution of moyamoya disease susceptibility polymorphism p.R4810K in RNF213 in East and Southeast Asian populations.Neurol Med Chir (Tokyo). 2012;52(5):299-303. doi: 10.2176/nmc.52.299. Neurol Med Chir (Tokyo). 2012. PMID: 22688066
-
Importance of RNF213 polymorphism on clinical features and long-term outcome in moyamoya disease.J Neurosurg. 2016 May;124(5):1221-7. doi: 10.3171/2015.4.JNS142900. Epub 2015 Oct 2. J Neurosurg. 2016. PMID: 26430847
-
The Association of the RNF213 p.R4810K Polymorphism with Quasi-Moyamoya Disease and a Review of the Pertinent Literature.World Neurosurg. 2017 Mar;99:701-708.e1. doi: 10.1016/j.wneu.2016.12.119. Epub 2017 Jan 5. World Neurosurg. 2017. PMID: 28063898 Review.
-
A new horizon of moyamoya disease and associated health risks explored through RNF213.Environ Health Prev Med. 2016 Mar;21(2):55-70. doi: 10.1007/s12199-015-0498-7. Epub 2015 Dec 10. Environ Health Prev Med. 2016. PMID: 26662949 Free PMC article. Review.
Cited by
-
HAPLN3 p.T34A contributes to incomplete penetrance of moyamoya disease in Chinese carrying RNF213 p.R4810K.Eur J Neurol. 2024 Dec;31(12):e16473. doi: 10.1111/ene.16473. Epub 2024 Sep 24. Eur J Neurol. 2024. PMID: 39315749 Free PMC article.
References
-
- Research Committee on the Pathology and Treatment of Spontaneous Occlusion of the Circle of Willis, Health Labour Sciences Research Grant for Research on Measures for Infractable Diseases Guidelines for diagnosis and treatment of moyamoya disease (spontaneous occlusion of the circle of Willis) Neurol Med Chir (Tokyo) 2012;52:245–266. doi: 10.2176/nmc.52.245. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources